Epratuzumab
Showing 1 - 25 of 42
Waldenstrom Macroglobulinemia Trial in New York (Epratuzumab (hLL2- anti-CD22 humanized antibody))
Terminated
- Waldenstrom Macroglobulinemia
- Epratuzumab (hLL2- anti-CD22 humanized antibody)
-
New York, New York
- +1 more
Aug 12, 2021
Non Hodgkin's Lymphoma, NHL, Aggressive NHL Trial in United States (Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab
Withdrawn
- Non Hodgkin's Lymphoma
- +3 more
- Veltuzumab and 90Y-Epratuzumab Tetraxetan
- +2 more
-
Newark, Delaware
- +6 more
Aug 12, 2021
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell Trial (radiolabeled epratuzumab)
Completed
- Non-Hodgkin's Lymphoma
- Lymphoma, B-Cell
- radiolabeled epratuzumab
- (no location specified)
Aug 12, 2021
Non-Hodgkins Lymphoma Trial in Philadelphia, Houston (hLL2 (epratuzumab))
Terminated
- Non-Hodgkins Lymphoma
- hLL2 (epratuzumab)
-
Philadelphia, Pennsylvania
- +1 more
Aug 12, 2021
Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)
Unknown status
- Lymphoma
- immunoscintigraphy
- technetium Tc 99m epratuzumab
-
Los Angeles, California
- +7 more
Aug 12, 2021
Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)
Unknown status
- Lymphoma
- immunoscintigraphy
- technetium Tc 99m epratuzumab
-
Los Angeles, California
- +7 more
Aug 12, 2021
Systemic Lupus Erythematosus Trial in Worldwide (Placebo, Epratuzumab)
Completed
- Systemic Lupus Erythematosus
- Placebo
- Epratuzumab
-
Birmingham, Alabama
- +132 more
Nov 20, 2020
Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,
Recruiting
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- +4 more
- ADCT-602
-
Monrovia, California
- +1 more
Dec 7, 2022
NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in United States (veltuzumab)
Completed
- NHL
- +17 more
- veltuzumab
-
Savannah, Georgia
- +4 more
Aug 12, 2021
Follicular Lymphoma Trial in New York (90Y-epratuzumab tetraxetan, veltuzumab)
Terminated
- Follicular Lymphoma
- 90Y-epratuzumab tetraxetan
- veltuzumab
-
New York, New YorkWeill Cornell Medical College
Jan 26, 2018
Systemic Lupus Erythematosus Trial in Worldwide (Epratuzumab, Placebo)
Completed
- Systemic Lupus Erythematosus
- Epratuzumab
- Placebo
-
Birmingham, Alabama
- +140 more
Aug 31, 2018
B ALL, CD22+ Expression, Refractory B-ALL Trial in France (Epratuzumab)
Completed
- B ALL
- +2 more
- Epratuzumab
-
Angers, France
- +10 more
Feb 26, 2018
Systemic Lupus Erythematosus Trial in Worldwide (Epratuzumab)
Completed
- Systemic Lupus Erythematosus
- Epratuzumab
-
Birmingham, Alabama
- +227 more
Sep 3, 2018
Recurrent Childhood Acute Lymphoblastic Leukemia Trial in Worldwide (L-asparaginase, doxorubicin HCl, therapeutic
Completed
- Recurrent Childhood Acute Lymphoblastic Leukemia
- L-asparaginase
- +13 more
-
Birmingham, Alabama
- +45 more
Nov 14, 2017
CD22+ Relapsed/Refractory B-ALL Trial in Clermont-Ferrand (90Y-epratuzumab tetraxetan, chemo/ immunotherapy)
Withdrawn
- CD22+ Relapsed/Refractory B-ALL
- 90Y-epratuzumab tetraxetan
- chemotherapy/ immunotherapy
-
Clermont-Ferrand, FranceCHU de Clermont-Ferrand
Jan 17, 2017
Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia Trial (90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG, Busulfan, allogeneic
Withdrawn
- Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
- 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG
- +4 more
- (no location specified)
Jan 17, 2017
Systemic Lupus Erythematosus Trial in Fukuoka, Kitakyusyu, Tokyo (Epratuzumab)
Completed
- Systemic Lupus Erythematosus
- Epratuzumab
-
Fukuoka, Japan
- +5 more
Apr 11, 2016
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia Trial in New York (hLL1)
Completed
- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia
-
New York, New YorkWeill Cornell Medical College
May 25, 2018
Systemic Lupus Erythematosus Trial in London (Epratuzumab sc, Epratuzumab iv)
Completed
- Systemic Lupus Erythematosus
- Epratuzumab sc
- Epratuzumab iv
-
London, United Kingdom01
May 11, 2015
Acute Lymphoblastic Leukemia Trial in Nantes (Epratuzumab and 90Y-Epratuzumab)
Unknown status
- Acute Lymphoblastic Leukemia
- Epratuzumab and 90Y-Epratuzumab
-
Nantes, FranceCHU Nantes
Jun 24, 2014
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia Trial in United Kingdom (humanised mAb, veltuzumab, humanised mAb
Unknown status
- Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
- humanised monoclonal antibody, veltuzumab
- +2 more
-
Birmingham, United Kingdom
- +9 more
Jul 11, 2014